Systemic administration of biNV-IL-15 achieves targeted delivery of IL-15 to tumor-specific T cells, diminishes non-specific systemic immune stimulation, and maximizes CTL activation to drive tumor killing and immunological memory. Here, IL15 is linked to neoplasm.